Unicycive resubmits kidney drug NDA after adding new manufacturing vendor

Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, a kidney disease treatment aimed at hyperphosphatemia in dialysis patients. The filing adds chemistry and manufacturing data from a new vendor as the company seeks FDA acceptance within 30 days and a new six-month review clock.

Why it matters: - Oxylanthanum carbonate is Unicycive Therapeutics’ lead program and a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis. - The resubmission moves the drug back into the FDA review process after prior manufacturing issues delayed approval. - Unicycive is aiming to preserve its launch timeline while building a second drug product supply source for redundancy.

What happened: - Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, or OLC, on Sept. 30, 2026. - The application covers OLC as an investigational oral phosphate binder for hyperphosphatemia in CKD patients on dialysis. - The company expects FDA acceptance of the NDA within 30 days. - Unicycive expects a new PDUFA date six months from the resubmission date. - The resubmission includes chemistry, manufacturing and controls data from a new third-party drug product manufacturing vendor.

The details: - The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status. - That FDA classification indicates the facility was in an acceptable state of current Good Manufacturing Practices compliance. - The new vendor’s CMC package includes technical specifications similar to the original third-party manufacturing vendor. - The new vendor has already manufactured OLC drug product and completed 12-month stability studies. - Unicycive also submitted additional in-vitro bridging data between the two vendors, following FDA guidance from earlier discussions. - The NDA is supported by three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers and a tolerability study in CKD patients on dialysis. - The filing also rests on multiple preclinical studies and CMC data. - As of June 30, 2026, unaudited cash, cash equivalents and marketable securities totaled $61.4 million. - Unicycive said that cash position supports OLC launch preparation and an expected cash runway into the second half of 2027. - OLC is being pursued through the FDA’s 505(b)(2) pathway. - The drug has issued composition-of-matter patents with exclusivity until 2031, with potential patent term extension until 2035.

Between the lines: - The FDA issued a Complete Response Letter in June 2026 tied to the same third-party manufacturing deficiencies cited in a June 2025 CRL. - The FDA did not raise clinical efficacy or safety concerns in the June 2026 CRL. - The FDA also did not request additional data from Unicycive. - The main obstacle has been the original vendor’s unreinspected facility, not the drug’s clinical package. - The original third-party manufacturer has received written notification that an FDA inspection has been assigned, but the inspection had not occurred as of Sept. 29, 2026. - If that inspection happens soon and the facility is found cGMP-compliant, Unicycive plans to seek FDA alignment on a shorter approval timeline. - Keeping both vendors would give Unicycive supply chain redundancy if the drug reaches market. - CEO Shalabh Gupta said the company believes the resubmission creates an efficient path to potential approval and is continuing commercial readiness work ahead of a possible launch.

What’s next: - The FDA must first decide whether to accept the resubmitted NDA. - If accepted, the review clock would restart with a new PDUFA date six months out. - FDA inspection of the original manufacturer could still affect the timing of any approval decision. - Unicycive will keep preparing for a possible commercial launch while the review moves forward.

The bottom line: - Unicycive is trying to clear a manufacturing roadblock, not a clinical one, as it makes another run at FDA approval for OLC.